Drug General Information |
Drug ID |
D01UYI
|
Former ID |
DNC004715
|
Drug Name |
CHRYSIN
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C15H10O4
|
Canonical SMILES |
C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O
|
InChI |
1S/C15H10O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-8,16-17H
|
InChIKey |
RTIXKCRFFJGDFG-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Aldose reductase |
Target Info |
Inhibitor |
[2]
|
Cytochrome P450 1B1 |
Target Info |
Inhibitor |
[1]
|
Cytochrome P450 19 |
Target Info |
Inhibitor |
[3]
|
3-oxoacyl-[acyl-carrier protein] reductase |
Target Info |
Inhibitor |
[4]
|
Cell division protein kinase 6 |
Target Info |
Inhibitor |
[5]
|
BioCyc Pathway
|
Methylglyoxal degradation III
|
Acetone degradation I (to methylglyoxal)PWY66-401:Superpathway of tryptophan utilization
|
Superpathway of melatonin degradation
|
Melatonin degradation IPWY-7305:Superpathway of steroid hormone biosynthesis
|
Estradiol biosynthesis II
|
Estradiol biosynthesis I
|
KEGG Pathway
|
Pentose and glucuronate interconversions
|
Fructose and mannose metabolism
|
Galactose metabolism
|
Glycerolipid metabolism
|
Metabolic pathwayshsa00140:Steroid hormone biosynthesis
|
Tryptophan metabolism
|
Metabolism of xenobiotics by cytochrome P450
|
Ovarian steroidogenesis
|
Chemical carcinogenesis
|
MicroRNAs in cancerhsa00140:Steroid hormone biosynthesis
|
Metabolic pathways
|
Ovarian steroidogenesishsa04110:Cell cycle
|
p53 signaling pathway
|
PI3K-Akt signaling pathway
|
Hepatitis B
|
Measles
|
Pathways in cancer
|
Viral carcinogenesis
|
MicroRNAs in cancer
|
Pancreatic cancer
|
Glioma
|
Melanoma
|
Chronic myeloid leukemia
|
Small cell lung cancer
|
Non-small cell lung cancer
|
NetPath Pathway
|
IL1 Signaling Pathway
|
TGF_beta_Receptor Signaling PathwayNetPath_23:TSH Signaling Pathway
|
IL4 Signaling Pathway
|
TGF_beta_Receptor Signaling PathwayNetPath_25:FSH Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
PANTHER Pathway
|
Androgen/estrogene/progesterone biosynthesis
|
Pathway Interaction Database
|
p73 transcription factor network
|
Coregulation of Androgen receptor activity
|
C-MYB transcription factor network
|
IL2 signaling events mediated by STAT5
|
Regulation of retinoblastoma protein
|
PathWhiz Pathway
|
Fructose and Mannose Degradation
|
Pyruvate Metabolism
|
Pterine Biosynthesis
|
Glycerolipid Metabolism
|
Galactose MetabolismPW000045:Androgen and Estrogen Metabolism
|
Reactome
|
Endogenous sterolsR-HSA-211976:Endogenous sterolsR-HSA-2559580:Oxidative Stress Induced Senescence
|
Senescence-Associated Secretory Phenotype (SASP)
|
Oncogene Induced Senescence
|
Cyclin D associated events in G1
|
WikiPathways
|
Metapathway biotransformation
|
Polyol Pathway
|
Metabolism of steroid hormones and vitamin DWP702:Metapathway biotransformation
|
Estrogen metabolism
|
Benzo(a)pyrene metabolism
|
Tamoxifen metabolism
|
Tryptophan metabolism
|
Oxidation by Cytochrome P450
|
Nuclear Receptors Meta-Pathway
|
Estrogen Receptor Pathway
|
Sulindac Metabolic Pathway
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
miR-targeted genes in adipocytes - TarBase
|
Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation
|
Ovarian Infertility Genes
|
Metabolism of steroid hormones and vitamin D
|
FSH signaling pathway
|
Integrated Breast Cancer Pathway
|
Phase 1 - Functionalization of compoundsWP707:DNA Damage Response
|
G1 to S cell cycle control
|
Wnt Signaling Pathway Netpath
|
Retinoblastoma (RB) in Cancer
|
Signaling Pathways in Glioblastoma
|
Metastatic brain tumor
|
miR-targeted genes in leukocytes - TarBase
|
Mitotic G1-G1/S phases
|
Cell Cycle
|
miRNAs involved in DNA damage response
|
miRNA Regulation of DNA Damage Response
|
References |
REF 1 | Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. Epub 2010 Jul 13.Selective inhibition of methoxyflavonoids on human CYP1B1 activity. |
---|
REF 2 | Bioorg Med Chem. 2010 May 1;18(9):3020-5. Epub 2010 Mar 27.Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. |
---|
REF 3 | Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. Epub 2010 Apr 8.Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). |
---|
REF 4 | J Med Chem. 2006 Jun 1;49(11):3345-53.Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. |
---|
REF 5 | J Med Chem. 2005 Feb 10;48(3):737-43.Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. |